2024 ICD-10-CM Diagnosis Code C55

by

Malignant neoplasm of uterus, part unspecified

  • C55 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2024 edition of ICD-10-CM C55 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of C55 – other international versions of ICD-10 C55 may differ.

ICD-10-CM Coding Rules

  • C55 is applicable to female patients.

The following code(s) above C55 contain annotation back-references

 that may be applicable to C55:

  • C00-D49  Neoplasms
  • C51-C58  Malignant neoplasms of female genital organs

Approximate Synonyms

  • Cancer of the uterus
  • Cancer of the uterus, leiomyosarcoma
  • Cancer of the uterus, sarcoma
  • Leiomyosarcoma of uterus
  • Malignant neoplasm of uterus
  • Primary malignant neoplasm of uterus
  • Sarcoma of uterus

Clinical Information

  • Cancer that forms in tissues of the uterus (the small, hollow, pear-shaped organ in a woman’s pelvis in which a fetus develops). Two types of uterine cancer are endometrial cancer (cancer that begins in cells lining the uterus) and uterine sarcoma (a rare cancer that begins in muscle or other tissues in the uterus).
  • Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.
  • The uterus, or womb, is an important female reproductive organ. It is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus. This type of cancer is sometimes called endometrial cancer. The symptoms of uterine cancer include
    • unusual vaginal bleeding or discharge
    • trouble urinating
    • pelvic pain
    • pain during intercourse
    uterine cancer usually occurs after menopause. Being obese and taking estrogen-alone hormone replacement therapy (also called menopausal hormone therapy) also increase your risk. Treatment varies depending on your overall health, how advanced the cancer is and whether hormones affect its growth. Treatment is usually a hysterectomy, which is surgery to remove the uterus. The ovaries and fallopian tubes are also removed. Other options include hormone therapy and radiation. nih: national cancer institute

ICD-10-CM C55 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 736 Uterine and adnexa procedures for ovarian or adnexal malignancy with mcc
  • 737 Uterine and adnexa procedures for ovarian or adnexal malignancy with cc
  • 738 Uterine and adnexa procedures for ovarian or adnexal malignancy without cc/mcc
  • 739 Uterine and adnexa procedures for non-ovarian and non-adnexal malignancy with mcc
  • 740 Uterine and adnexa procedures for non-ovarian and non-adnexal malignancy with cc
  • 741 Uterine and adnexa procedures for non-ovarian and non-adnexal malignancy without cc/mcc
  • 754 Malignancy, female reproductive system with mcc
  • 755 Malignancy, female reproductive system with cc
  • 756 Malignancy, female reproductive system without cc/mcc

Convert C55 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change